Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $2.1 million.

  • Gyre Therapeutics' Cash from Financing Activities rose 12.65% to $365,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 52.79%. This contributed to the annual value of $2.1 million for FY2024, which is 15.92% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Cash from Financing Activities of $2.1 million as of FY2024, which was down 15.92% from $2.5 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Cash from Financing Activities registered a high of $60.4 million during FY2020, and its lowest value of -$45.0 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $2.1 million (2024), whereas its average is -$13.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 18,363.61% in 2020, then slumped by 190.83% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Cash from Financing Activities (Yearly) stood at $60.4 million in 2020, then declined by 17.93% to $49.6 million in 2021, then crashed by 190.83% to -$45.0 million in 2022, then spiked by 105.55% to $2.5 million in 2023, then declined by 15.92% to $2.1 million in 2024.